Parkinson's Disease: Diagnostics & Clinical Trials

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement. This feed focuses on therapeutic aspects, diagnostic tools including medical imaging, and clinical trials in PD.

January 19, 2021

Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis

Aging
LiQin ShengPingLei Pan
January 12, 2021

Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications

Movement Disorders Clinical Practice
Jared T HinkleGregory M Pontone
January 16, 2021

Unilateral pallidothalamic tractotomy for akinetic-rigid Parkinson's disease: a prospective open-label study

Journal of Neurosurgery
Shiro HorisawaTakaomi Taira
January 12, 2021
Review
Open Access

Clinical outcomes in elective total hip arthroplasty in Parkinson's disease: a systematic review of the literature

EFORT Open Reviews
Andreas FontalisEleftherios Tsiridis
January 15, 2021
Open Access

Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease

Scientific Reports
Gabriella HernadiGabor Perlaki
January 12, 2021

Opicapone: A Review in Parkinson's Disease

CNS Drugs
Lesley J Scott
January 21, 2021
Open Access

Nordic Walking and Free Walking Improve the Quality of Life, Cognitive Function, and Depressive Symptoms in Individuals with Parkinson's Disease: A Randomized Clinical Trial.

Journal of Functional Morphology and Kinesiology
Elren Passos-MonteiroLeonardo Alexandre Peyré-Tartaruga
January 20, 2021

Hyperhomocysteinemia and Dementia Associated With Severe Cortical Atrophy, but No Amyloid Burden

Journal of Geriatric Psychiatry and Neurology
Alessandro Reffo, Carlo Gabelli
January 13, 2021
Review
Open Access

Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
David J Brooks
January 18, 2021

Applying available knowledge and resources to alleviate familial and sporadic neurodegenerative disorders

Progress in Molecular Biology and Translational Science
Mark P Mattson
January 17, 2021
Open Access

Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling

NPJ Parkinson's Disease
Esther A PelzerLars Timmermann
January 12, 2021

Psychomotor processing and functional decline in Parkinson's disease predicted by the Purdue Pegboard Test

International Journal of Geriatric Psychiatry
Jared T Hinkle, Gregory M Pontone
January 15, 2021
Review
Open Access

A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach

Digital Biomarkers
Lynn RochesterRonenn Roubenoff

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

AFM in situ DNA

AFM in situ DNA describes in situ analysis (or study) of DNA using atomic force microscopy. Discover the latest research on AFM in situ DNA here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

© 2021 Meta ULC. All rights reserved
/feed-previews/parkinsons-disease-diagnostics-and-clinical/6034e3fd-2763-4cbc-860f-f5877e3d6425